BehaveNet^® Clinical Capsule™:

drug: venlafaxine

• Clinical class: antidepressant
• Action: selective serotonin norepinephrine reuptake inhibitor
• CSA schedule: none
• DEA number: none
• MEDLINEplus^® Drug Information

U.S. Preparations:

• Effexor^® (Wyeth-Ayerst) FDA approved:
  Depression 10.20.1997;
  Generalized Anxiety Disorder 3.11.99
  prevention of recurrence of depression and for the prevention of relapse of depression 5.2.2001
  Social Anxiety Disorder 2.11.2003
  U.S. Prescribing Information
• Effexor^® XR: (Wyeth-Ayerst) FDA approved:
  Depression 10.20.1997
  Generalized Anxiety Disorder 3.11.99
  prevention of recurrence of depression and for the prevention of relapse of depression 5.2.2001
  Social Anxiety Disorder 2.11.2003
  Treatment of long term and short term Panic Disorder 11.18.2005
  U.S. Prescribing Information

Preparations Outside U.S.:

• Dobupal, EFectin, Efexir, Efexor^®, Trevilor, Trewilor, Vandral

Stephen Stahl's Clinical Pearls* (Consult your physician before making any change in your treatment.)

• Three drugs in one:
  • SSRI at low doses (essentially a twice a day SSRI)
  • Add NE uptake blockade at medium doses.
  • Add DA reuptake at high to very high doses.
• Choose the dose, and therefore choose which drug you want.
• No advantage over SSRI at low doses.
• Possibly more rapid in onset of action than other antidepressants.
• Possibly useful at medium to very high doses for cases refractory to SSRIs.
• Not well tolerated at medium to high doses.
• Zolpidem or trazodone may be useful for venlafaxine's insomnia.
• Mirtazapine (Remeron) may be useful for venlafaxine's nausea, insomnia and agitation.
• Venlafaxine withdrawal effects common (GI, dizziness, sweating, etc);
• Controlled release formulation in testing for once a day use; until then use twice daily dosing.
• Low likelihood of drug interactions (other than MAOIs).

http://www.behavenet.com/capsules
Search Capsules™ | Terms of Use | Request New Term
Capsules™ Copyright © 1997-2007 BehaveNet®